Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study

Blood Neoplasia (2025) 2 (2): 100075.

https://doi.org/10.1016/j.bneo.2025.100075

Published: 2025

Journal Articles

A feedforward loop between ACLY and MYC supports T-ALL progression in vivo

Victoria da Silva-Diz, Amartya Singh, Maya Aleksandrova, Oekyung Kim, Christopher Thai, Olga Lancho, Patricia Renck Nunes, Hayley Affronti, Alexia Martínez de Paz, Steven Z. Josefowicz, Xiaoyang Su, Kathryn E. Wellen, Daniel Herranz

Blood Neoplasia (2025) 2 (2): 100069.

https://doi.org/10.1016/j.bneo.2025.100069

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma

Blood Neoplasia (2025) 2 (2): 100072.

https://doi.org/10.1016/j.bneo.2025.100072

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell sequencing reveals shared clonal signatures in nonmalignant B and tumor cells in T-prolymphocytic leukemia

Caroline Hesselager, Ingrid Thörn, Millaray Marincevic, Claes Ladenvall, Jonas Almlöf, Sara Löfgren, Simone Weström, Helena Nord, Lesley-Ann Sutton, Lucia Cavelier, Panagiotis Baliakas, Rose-Marie Amini

Blood Neoplasia (2025) 2 (2): 100076.

https://doi.org/10.1016/j.bneo.2025.100076

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis

Dai Chihara, Shibing Yang, Savreet Bains Chawla, Guihua Zhang, Anthony Wang, Junhua Yu, Donald Arnette, Fernando Rivas Navarro, Julie Blaedel, Alex Mutebi

Blood Neoplasia (2025) 2 (2): 100080.

https://doi.org/10.1016/j.bneo.2025.100080

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study

Blood Neoplasia (2025) 2 (1): 100063.

https://doi.org/10.1016/j.bneo.2024.100063

Published: 2025

Includes: Supplemental data

Journal Articles

Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis

Rodrigo Fonseca, Alex J. Liu, Blake T. Langlais, Diana Almader-Douglas, Holenarasipur R. Vikram, Talal Hilal

Blood Neoplasia (2025) 2 (1): 100061.

https://doi.org/10.1016/j.bneo.2024.100061

Published: 2025

Includes: Supplemental data

Journal Articles

Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma

Bei Wang, Benjamin A. Derman, Madina Sukhanova, Daniel Appelbaum, John Cursio, Wei Zhang, Andrzej Jakubowiak, Brian C.-H. Chiu

Blood Neoplasia (2025) 2 (1): 100065.

https://doi.org/10.1016/j.bneo.2024.100065

Published: 2025

Journal Articles

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma

Blood Neoplasia (2025) 2 (1): 100051.

https://doi.org/10.1016/j.bneo.2024.100051

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Ramsay Hafer, Francesco Iadevaia, Thomas Z. Rohan, Teresa Duong, Maria Poluch, Gina Keiffer, Michael Li, Andres Ferber, Luca Laurenti, Alan S. Khoo, Pierluigi Porcu

Blood Neoplasia (2025) 2 (1): 100064.

https://doi.org/10.1016/j.bneo.2024.100064

Published: 2025

Includes: Supplemental data

Journal Articles

Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia

Olivia M. Depies, Qianqian Guo, Yuan Gao, Sutapa Sinha, Zhenqing Ye, Weiguo Han, Kari G. Rabe, Mingma S. Hoel, Heather C. Darby, Chuanhe Yu, Esteban Braggio, Sameer A. Parikh, Susan L. Slager, Neil E. Kay, Zhiquan Wang

Blood Neoplasia (2025) 2 (1): 100059.

https://doi.org/10.1016/j.bneo.2024.100059

Published: 2025

Includes: Supplemental data

Journal Articles

Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL

Willem P. J. Cox, Noël M. M. Dautzenberg, Linde Dekker, Tesa Klenovsek, Annelisa M. Cornel, Marliek van Hoesel, Dorette S. van Ingen Schenau, Reno S. Bladergroen, Roland P. Kuiper, Laurens T. van der Meer, Friso G. Calkoen, Stefan Nierkens, Frank N. van Leeuwen

Blood Neoplasia (2025) 2 (1): 100060.

https://doi.org/10.1016/j.bneo.2024.100060

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Hiroki Kobayashi, Ryota Chijimatsu, Yusuke Naoi, Yoshihiro Otani, Ryo Mizuta, Kentaro Fujii, Joji Ishida, Hiroyuki Murakami, Hideki Ujiie, Kazuhiro Ikeuchi, Tomohiro Urata, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Nobuharu Fujii, Ken-ichi Matsuoka, Yasuharu Sato, Yoshinobu Maeda, Daisuke Ennishi

Blood Neoplasia (2025) 2 (1): 100058.

https://doi.org/10.1016/j.bneo.2024.100058

Published: 2025

Includes: Supplemental data

Journal Articles

Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

Julia Erin Wiedmeier-Nutor, Michael A. Golafshar, Katie L. Kunze, Edward D. Esplin, Robert L. Nussbaum, Erik Jessen, Brandie Heald, A. Keith Stewart, N. Jewel Samadder, P. Leif Bergsagel, Rafael Fonseca

Blood Neoplasia (2024) 2 (1): 100045.

https://doi.org/10.1016/j.bneo.2024.100045

Published: 2024

Includes: Supplemental data

Journal Articles

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol

David T. Yeung, Laura N. Eadie, Jacqueline Rehn, Susan L. Heatley, Barbara J. McClure, Elyse C. Page, Caitlin E. Schutz, Michael P. Osborn, Toby Trahair, Rosemary Sutton, Michelle J. Henderson, John Kwan, Sally Mapp, Luciano Dalla-Pozza, Kenneth Bradstock, Matthew Greenwood, Deborah L. White

Blood Neoplasia (2024) 2 (1): 100041.

https://doi.org/10.1016/j.bneo.2024.100041

Published: 2024

Includes: Supplemental data

Journal Articles

Cerebrospinal fluid attenuates the efficacy of methotrexate against acute lymphoblastic leukemia cells

Jongseok Kang, Jason Ostergaard, Xiaohong Wang, Peter M. Gordon

Blood Neoplasia (2024) 2 (1): 100057.

https://doi.org/10.1016/j.bneo.2024.100057

Published: 2024

Includes: Supplemental data

Journal Articles

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

Swaminathan P. Iyer, Shaker Dakhil, Michi M. Shinohara, Jasmine Zain, Mark Acosta, Francine Foss

Blood Neoplasia (2024) 2 (1): 100055.

https://doi.org/10.1016/j.bneo.2024.100055

Published: 2024

Journal Articles

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Matthew S. Davids, Jacob Ambrose, Enrico de Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z. H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching Kun Wang, Mazyar Shadman

Blood Neoplasia (2024) 2 (1): 100047.

https://doi.org/10.1016/j.bneo.2024.100047

Published: 2024

Includes: Supplemental data

Journal Articles

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study

Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Kouhei Yamamoto, Norio Shimizu, Ryuji Koike, Ayako Arai

Blood Neoplasia (2024) 2 (1): 100053.

https://doi.org/10.1016/j.bneo.2024.100053

Published: 2024

Includes: Supplemental data

Journal Articles

Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies

Lawrence A. Stern, Vibhuti Vyas, Laura Lim, Christian Huynh, Ryan Urak, Ruby Espinosa, Zhiqiang Wang, Michalina Silva Thiel, John C. Williams, Stephen J. Forman, Christine E. Brown, Xiuli Wang

Blood Neoplasia (2024) 1 (4): 100048.

https://doi.org/10.1016/j.bneo.2024.100048

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study

A feedforward loop between ACLY and MYC supports T-ALL progression in vivo

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma

Single-cell sequencing reveals shared clonal signatures in nonmalignant B and tumor cells in T-prolymphocytic leukemia

Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis

Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study

Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis

Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma

Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia

Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol

Cerebrospinal fluid attenuates the efficacy of methotrexate against acute lymphoblastic leukemia cells

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study

Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only